Related content

The Oral NK 1 Antagonist Aprepitant for Prevention of Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

By Ronald de Wit  

American Journal of Cancer, Vol. 4, Iss. 1, 2005-01 ,pp. : 35-48

Adis International

Access to resources Recommend Favorite

A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application

By Veltkamp S.   Alderden-Los C.   Sharma A.   Rosing H.   Beijnen J.   Schellens J.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 43-50

Springer Publishing Company

Access to resources Recommend Favorite

The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer

By              

International Journal of Oncology, Vol. 45, Iss. 4, 2014-01 ,pp. : 1658-1672

Spandidos Publications

Access to resources Recommend Favorite

Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide

By Hesketh Paul   Younger Jerry   Sanz-Altamira Pedro   Hayden Melissa   Bushey Julie   Trainor Brian   Krentzin Michael   Nowd Peter   Arnaoutakis Konstantinos   Hesketh Ann  

Supportive Care in Cancer, Vol. 17, Iss. 8, 2009-08 ,pp. : 1065-1070

Springer Publishing Company

Access to resources Recommend Favorite

Painrelieving effect of a compound isolated from white peony root oral liquid on acute radiationinduced esophagitis

By                

Molecular Medicine Reports, Vol. 7, Iss. 6, 2013-01 ,pp. : 1950-1954

Spandidos Publications

Access to resources Recommend Favorite